Better Plant Receives Health Canada Approval for Plant-Based Pain Balm

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) ("Better Plant") or (the "Company") announces that its subsidiary Urban Juve Provisions Inc., has received a Natural Health Product ("NHP") number from Health Canada for its proprietary plant-based pain balm. Health Canada's Natural and Non-Prescription Health Products Directorate has concluded that Urban Juve's application is in compliance pursuant to section 7 of the Natural Health Products Regulations and issued NHP number 80105503.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/66589_7a185ef02486d86b_001.jpg

Better Plant Receives Health Canada Approval for Plant-Based Pain Balm

To view an enhanced version of image, please visit:
https://orders.newsfilecorp.com/files/6377/66589_7a185ef02486d86b_001full.jpg

"We are thrilled that our unique pain relief formula based on Ayurvedic principles is now approved by Health Canada," says Penny White, CEO of Better Plant. "This allows us to sell and distribute the product ourselves with the potential to white label the product with other strategic partners and brands."

All-natural health products sold in Canada require premarket approval. The health claim that was approved for Urban Juve's pain balm efficacy is: "temporarily relieves back aches and pains of muscles and joints associated with one or more of the following: simple backache, lumbago, strains and sprains (involving muscles, tendons, and/or ligaments), and arthritis."

"One has to think one step ahead to anticipate the challenges for regulatory approvals of NHP products," says Bhavna Solecki Director of Product Research for Better Plant. "We have been successful obtaining multiple NHP approvals, which we are very proud of, considering the required health claim substantiation, theoretical product review, scientific literature review and product classification."

Better Plant's pain balm uses a synergetic and proprietary blend of plant-based ingredients. Menthol crystals act as an anti-irritant and provide a heating/cooling effect by sending a signal to the brain which interprets the feeling as cold, relieving the uncomfortable heat of inflammation.

Some studies estimate that up to 40% of the population suffers from chronic pain. Arthritis is the most prevalent health condition in Canada, and its most common form is osteoarthritis which is a leading cause of disability worldwide. Other common causes of chronic pain include gout, rheumatoid arthritis, fibromyalgia, lupus and carpal tunnel syndrome which is increasingly affecting youth, from excessive typing and texting.

According to a report by BCC Research, the global market for pain management will grow from nearly USD$36.1 billion in 2017 to USD$52.0 billion by 2022, with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.

About Better Plant Sciences Inc.

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas. It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based-products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its 51% majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion's mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, "forward looking statements") under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company's products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66589

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
Field of cannabis plants under bright sunlight.

Cannabis Market Update: H1 2025 in Review

The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...

Latest Press Releases

Related News